Why We Invested In FidoCure aka How Tech Can Help Save Dogs (And Eventually Humans) From Cancer

2 min read

In October FidoCure, also known as One Health Company, announced a $10M series A led by Polaris Ventures and we increased our position given our continued excitement. Tau Ventures, an AI-first seed fund in Silicon Valley, was first an investor in the seed led by Andreessen-Horwitz. FidoCure helps provide cancer treatments for dogs and eventually could improve it for humans too. The company is a graduate of YCombinator and impressed us with (1) a strong need, (2) building an execution-focused team, and (3) creating a differentiated product. 1) The Need 6M dogs in the US get cancer every year compared…...

This article is free to read

Login to read the full article


OR

By subscribing to our main site, you will also be subscribed to DDIntel - our regular letter showcasing our featured articles and applications.

Amit Garg I have been in Silicon Valley for 20 years -- at Samsung NEXT Ventures, running my own startup (as of May 2019 a series D that has raised $120M and valued at $450M), at Norwest Ventures, and doing product and analytics at Google. My academic training is BS in computer science and MS in biomedical informatics, both from Stanford, and MBA from Harvard. I speak natively 3 languages, live carbon-neutral, am a 70.3 Ironman finisher, and have built a hospital in rural India serving 100,000 people.